GW Pharmaceuticals is reportedly preparing itself for takeover approaches as its attractiveness continues to grow with the increasing potential of its cannabinoid portfolio.
According to Reuters, the british biotech has called in investment back Morgan Stanley to help it deal with suitors, which it says remain unidentified at this point but might include GW’s distribution partners for the marijuana-based multiple sclerosis spray Sativex.
Citing people familiar with the situation, Reuters also reported that the company is not currently interested in exploring a sale and it remain uncertain whether a deal will actually occur.
There has been growing interest in GW because of its novel cannabis-based epilepsy therapies. Its flagship drug, Epidiolex, has recently racked up a number of late-stage trial successes in patients with the rare conditions Dravet